Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

about

Antibodies in the treatment of aplastic anemia.Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.

P2860

Q37981576-3CB52F51-DB47-4187-891C-0AB5D3FBD5E0 Q45068889-D9CDE144-4AEC-4211-AB58-CB72851CBB51

P2860

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

Item

http://www.wikidata.org/entity/Q42743020

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@en

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@nl

type

Item

label

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@en

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@nl

prefLabel

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@en

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@nl

P1476

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

@en

P2093

Evan B Shereck

http://www.w3.org/2001/XMLSchema#string

Peter Kurre

http://www.w3.org/2001/XMLSchema#string

Rebecca J Deyell

http://www.w3.org/2001/XMLSchema#string

P2860

Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells

Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).

Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

Pathophysiology and management of inherited bone marrow failure syndromes.

Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going.

[Prognostic factors of immunosuppressive therapy in children acquired aplastic anemia].

P304

793-795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2011.044917

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51184134

http://www.w3.org/2001/XMLSchema#string

P698

21632841

http://www.w3.org/2001/XMLSchema#string

P932

3105637

http://www.w3.org/2001/XMLSchema#string

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

about

P2860

P2860

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932